Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

50.80USD
24 Jul 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$50.80
Open
$50.81
Day's High
$50.99
Day's Low
$50.47
Volume
8,584,349
Avg. Vol
6,476,354
52-wk High
$51.13
52-wk Low
$37.38

Latest Key Developments (Source: Significant Developments)

Abbott Q2 adjusted EPS $0.62 from continuing operations excluding items
Thursday, 20 Jul 2017 07:45am EDT 

July 20 (Reuters) - Abbott Laboratories ::Abbott reports second-quarter 2017 results.Q2 adjusted earnings per share $0.62 from continuing operations excluding items.Q2 gaap earnings per share $0.15 from continuing operations.Q2 earnings per share view $0.61 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $2.43 to $2.53 from continuing operations.Sees FY 2017 gaap earnings per share $1.03 to $1.13 from continuing operations.Q2 sales $6.6 billion versus I/B/E/S view $6.63 billion.Abbott Laboratories - ‍second-quarter worldwide sales of $6.6 billion increased 24.4 percent on a reported basis​.Abbott Laboratories qtrly total diagnostics sales $‍1,273​ million, up 3.8 percent on a reported basis.Abbott Laboratories - Q2 total vascular sales $731‍​ million, up 6.6 percent on a reported basis.Abbott Laboratories - qtrly total pediatric sales $‍​987 million, up 1.4 percent on a reported basis.Q2 total nutrition sales $1,731 million, down 0.6 percent on a reported basis.FY 2017 earnings per share view $2.47 -- Thomson Reuters I/B/E/S.Says ‍raises full-year 2017 EPS guidance range for continuing operations​.Abbott Laboratories - ‍sales growth in quarter impacted by purchasing patterns associated with implementation of new goods and services tax system in India​.  Full Article

Abbott, Bigfoot Biomedical enter deal to develop diabetes management systems
Thursday, 13 Jul 2017 07:30am EDT 

July 13 (Reuters) - Abbott Laboratories ::Abbott Laboratories and Bigfoot Biomedical enter agreement to develop and commercialize diabetes management systems.Abbott says financial terms of the agreement with Bigfoot are not being disclosed.Abbott says will supply glucose measurement sensors for all of Bigfoot's insulin delivery systems in U.S. as exclusive sensors for those systems.Bigfoot will develop and commercialize multiple systems using Abbott's freestyle libre sensor technology.In the U.S., freestyle libre system is currently pending approval by the U.S. Food and Drug Administration.  Full Article

Abbott sets quarterly dividend of $0.265 per share
Friday, 9 Jun 2017 10:15am EDT 

June 9 (Reuters) - Abbott :Sets quarterly dividend of $0.265 per share.  Full Article

Alere Q4 loss per share $1.38 from continuing operations
Monday, 5 Jun 2017 04:39pm EDT 

June 5 (Reuters) - Alere Inc ::Alere files form 10-k, reports fourth quarter and full year 2016 financial results.Q4 gaap loss per share $1.38 from continuing operations.Q4 revenue $597 million versus I/B/E/S view $607.4 million.Q4 earnings per share view $0.50 -- Thomson Reuters I/B/E/S.Alere Inc - ‍abbott transaction is expected to close by end of q3 of 2017​.Alere Inc - ‍due to pending transaction with Abbott, Alere will no longer hold conference calls to discuss its quarterly financial results​.  Full Article

Abbott reports CE Mark for tacticath contact force ablation catheter
Tuesday, 9 May 2017 09:00am EDT 

May 9 (Reuters) - Abbott Laboratories ::Abbott announces CE Mark for tacticath™ contact force ablation catheter, sensor enabled™.Abbott Laboratories - currently tacticath contact force ablation catheter is available in select markets in europe; full market release expected in q3.  Full Article

Abbott Laboratories develops 2 new science-based nutrition drinks for patients undergoing surgery
Wednesday, 26 Apr 2017 08:00am EDT 

April 26 (Reuters) - Abbott Laboratories ::Abbott Laboratories - developed two new science-based nutrition drinks for patients undergoing surgery.  Full Article

Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call
Wednesday, 19 Apr 2017 10:41am EDT 

April 19 (Reuters) - Abbott Laboratories :Abbott CEO says "the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space" - Conf Call.Abbott CEO says "the integration of St. Jude is going well and we're on track to achieve our projected synergy targets" - Conf Call.Abbott CEO says financial impact of Alere acquisition to be revealed at a later date - Conf Call.Abbott CEO says Q2 adjusted EPS forecast of $0.59 to $0.61 - Conf Call.Abbott CEO says "in nutrition, we now forecast low single-digit sales growth for both the second quarter and the full year" - Conf Call.Abbott CFO "look, the compay's (Alere) has had some challenges. We all know that and it's a bit of a fixer-upper and we know that, I'd say we're pleased to have the resolution of this matter behind us" - Conf Call.Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call.Abbott CFO on warning letter: "Not going to change our launch dates or assumptions on approval dates because I don't see a reason to do that yet".Abbott CEO:"We still like the long term prospect of China (as it relates to the nutrition market)".Abbott Exec - Demonitization in India modestly impacted Abbott results. That impact is diminishing and will continue to diminish.Abbott Exec - With respect to India's goods and services tax, Abbott is monitoring that, because time line has been a "little bit fluid".  Full Article

Abbott Q1 adjusted earnings per share $0.48 from continuing operations
Wednesday, 19 Apr 2017 07:45am EDT 

April 19 (Reuters) - Abbott Laboratories ::Abbott reports first-quarter 2017 results.Q1 adjusted earnings per share $0.48 from continuing operations.Q1 GAAP earnings per share $0.22 from continuing operations.Q1 earnings per share view $0.43 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $2.40 to $2.50 from continuing operations.Q1 sales $6.3 billion versus I/B/E/S view $6.16 billion.Abbott Laboratories - Q1 worldwide sales of $6.3 billion increased 29.7 percent on a reported basis and 3.2 percent on a comparable operational basis.Q1 total nutrition sales $1,642 million, down 1.7 percent on reported basis.Abbott's full-year earnings-per-share guidance remains unchanged.Abbott Laboratories says q1 total pediatric sales $927 million, down 4.1 percent on a reported basis.Abbott Laboratories - Q1 total diagnostics sales $1,158 million, up 3.6 percent on a reported basis.Abbott Laboratories - Q1 total vascular sales $703 million, up 16.9 percent on a reported basis.Abbott-Integration of St. Jude going well, recently launched products contributing to double-digit sales growth across several areas of medical devices unit.  Full Article

Abbott Laboratories to buy Alere for $51 per share - FT, citing sources
Friday, 14 Apr 2017 03:08am EDT 

Abbott Laboratories : Abbott laboratories has ended protracted legal battle over its $5 bln plan to buy alere by agreeing to purchase smaller u.s. Rival at a lower price - FT .Abbott will pay $51 a share to acquire the diagnostic testing group instead of the earlier $56-a-share price - FT, citing sources.  Full Article

U.S. FDA says issued a warning letter to Abbott Laboratories
Thursday, 13 Apr 2017 10:15am EDT 

U.S. Food and Drug Administration : Says issued a warning letter to Abbott Laboratories . Says raises quality concerns after inspection of St. Jude's Sylmar facility .Says to Abbott failure to correct violations may result in regulatory action without further notice.  Full Article

BRIEF-Alere Inc enters into purchase agreement with Siemens Diagnostics ​‍​

* Says ‍on July 21, 2017, Alere entered into purchase agreement with Siemens Diagnostics Holding II B.V. ​‍​